Henney Nominated for FDA Commissioner

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

WASHINGTON--President Clinton has nominated Jane E. Henney, MD, vice president for health sciences, University of New Mexico, as the new FDA Commissioner. She would replace David M. Kessler, MD, who resigned more than a year ago and is now dean of the Yale University School of Medicine.

WASHINGTON--President Clinton has nominated Jane E. Henney, MD, vice president for health sciences, University of New Mexico, as the new FDA Commissioner. She would replace David M. Kessler, MD, who resigned more than a year ago and is now dean of the Yale University School of Medicine.

Dr. Henney, a cancer specialist, has served in government under every president since Jimmy Carter. She was the FDA’s deputy commissioner for operations from 1992 to 1994.

Her nomination won warm praise from many in the medical and public health fields, including Health and Human Services Secretary Donna E. Shalala, PhD. The Secretary called Dr. Henney "a talented manager" with "the solid medical and academic credentials that are needed to understand the burgeoning field of biomedical research."

However, several conservative Republicans have indicated their opposition to Dr. Henney. They want to know specifically if she had anything to do with the FDA’s decision to allow testing of the abortion drug RU-486.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content